Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634088 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
A Phase 1 study, sponsored by R-Pharm.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00634088 is a Phase 1 study that was terminated before completion, run by R-Pharm. The registered enrollment target is 13 participants.
The verdict
NCT00634088, a Phase 1 study, was terminated before completion, sponsored by R-Pharm.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and preliminary effectiveness of ixabepilone plus lapatinib with and without capecitabine in the treatment of human epidermal growth factor receptor 2 (HER2)-positive or metastatic breast cancer.
Interventions
- DRUG Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg
- DRUG Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg
- DRUG Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg
- DRUG Ixabepilone + Lapatinib + Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00634088
The ClinicalTrials.gov registry entry for NCT00634088 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is R-Pharm, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg is the first listed.
NCT00634088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00634088 about?
NCT00634088 is a clinical study titled "Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer". The purpose of this study is to determine the safety and preliminary effectiveness of ixabepilone plus lapatinib with and without capecitabine in the treatment of human epidermal growth factor receptor 2 (HER2)-positive or metastatic breast cancer.
What is the current status of trial NCT00634088?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2008-06. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00634088?
The interventions under investigation include: Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg (DRUG), Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg (DRUG), Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg (DRUG), Ixabepilone + Lapatinib + Capecitabine (DRUG).
Who is sponsoring clinical trial NCT00634088?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.